Abstract:Background Rheumatoid arthritis (RA) is a chronic inflammatory disease that results in destruction of joint cartilage and bone. However, many patients do not achieve satisfactory disease control by current therapy with high risk of adverse reactions. We have reported that absolute number of peripheral regulatory T (Treg) cells reduced in RA patients (EULAR Abstract). Moreover, rapamycin has been reported to inhibit differentiation of Th17 and promote growth of FoxP3 +Treg cells by inhibiting mTOR pathway [1]. Objectives To observe the therapeutic efficacy of rapamycin on the reduction of disease activity, increase in Tregs and decrease in Th17 to restore balance of Th17/Treg cells in RA patients with high disease activity (DAS28 ≥2.6). Methods Fifty RA patients who treated with two kinds of DMARDs for more than half a year did not achieve remission (DAS28 ≥2.6) were enrolled and were treated with rapamycin at a dose of 0.5 mg every 2 days for 24 weeks. The absolute number of CD4 +T cell subsets in peripheral blood from these patients were assessed by flow cytometry combined with internal standard beads before the treatment as baseline and at week 24 after treatment. Meantime, the DAS28, the dosage of corticosteroids and immunosuppressant were also recorded. Results Rapamycin treatment reduced the disease activity and induced remission (DAS28<2.6) in 44.9% of active RA patients. Their DAS28 was reduced from a median 2.9 (at week 0) to 1.9 (at week 24) (P<0.001) and the absolute number of peripheral Treg cells was increased from 27.14±15.11 cells/µl (at week 0) to 36.59±17.23 cells/µl (at week 24) (p=0.002). The ratios of Th17/Treg cells also had a significant decrease from 0.36±0.29 at baseline to 0.27±0.20 at week 24 (P<0.041). In contrast, the decrease in the absolute number of Th17 cells was not statistically significant (p=0.846). After the treatment, the proportion of patients taking glucocorticoids decreased from 66.0% to 64.0% and the mean dosage of prednisone decreased from 9.89 mg/d to 7.70 mg/d. And the usages of DMARDs were also reduced (P<0.001). Conclusions Rapamycin combined with low level of conventional therapy effectively reduced disease activity and induced remission among RA patients who received long-term conventional treatment without remission (DAS28 ≥2.6) by increasing the absolute number of Treg cells and restoring the balance of Th17 cells and Treg cells. As the research progresses, rapamycin is likely to become a promising therapeutic candidate. Reference [1] Shan J, Feng L, Sun G, et al. Interplay between mTOR and STAT5 signaling modulates the balance between regulatory and effective T cells. Immunobiology2015;220(4):510–517. Disclosure of Interest None declared

Augmenting regulatory T cells: new therapeutic strategy for rheumatoid arthritis

SAT0213 Low Dose Il-2 Restores Decreased Absolute Number of Regulatory T Cells and Imbalance Between Th17 and Regulatory T Cells in Patients with Rheumatoid Arthritis

Exploring the therapeutic potential of regulatory T cell in rheumatoid arthritis: Insights into subsets, markers, and signaling pathways

Regulatory T cells as a potent target for controlling bone loss.

Function and Role of Regulatory T Cells in Rheumatoid Arthritis

Regulatory T cells in rheumatoid arthritis: functions, development, regulation, and therapeutic potential

SAT0163 Absolute Number of Peripheral Cd4-Cd25+foxp3+t Cells Decreases and Restores after Low-Dose Interleukin-2 Treatment in Rheumatoid Arthritis

AB0382 Rapamycin Selectively Increases Circulating Tregcellsand Maintain Remission of Patients with Rheumatoid Arthritis

FRI0063 Rapamycin Induces Remission in Patients with Refractory Rheumatoid Arthritis

Regulatory T lymphocytes as a treatment method for rheumatoid arthritis - Superiority of allogeneic to autologous cells

Dysfunctions, Molecular Mechanisms, and Therapeutic Strategies of Regulatory T Cells in Rheumatoid Arthritis

Reestablish immune tolerance in rheumatoid arthritis

Promising Therapeutic Targets for Treatment of Rheumatoid Arthritis

Therapeutic Effect of Exogenous Regulatory T Cells on Collagen-induced Arthritis and Rheumatoid Arthritis

Impaired Tip60-mediated Foxp3 Acetylation Attenuates Regulatory T Cell Development in Rheumatoid Arthritis.

Manipulating Regulatory T Cells: a Promising Strategy to Treat Autoimmunity.

The role, targets and mechanisms of traditional Chinese medicine in regulating the balance of T helper type 17/regulatory Tcells in rheumatoid arthritis

CRISPR and personalized Treg therapy: new insights into the treatment of rheumatoid arthritis

Treg-targeted efficient-inducible platform for collagen-induced arthritis treatment

Increased Circulating Follicular Treg Cells Are Associated with Lower Levels of Autoantibodies in Patients with Rheumatoid Arthritis in Stable Remission.

Vaccination With Selected Synovial T Cells In Rheumatoid Arthritis